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Abstract
A nuanced understanding of HIV-positive status disclosure is urgently needed to inform the 
implementation of prevention interventions, including TasP and PrEP. To provide such 
understanding for the high HIV-burden setting of rural KwaZulu-Natal, we conducted a 
prospective cohort study to characterize determinants and trends in HIV-positive status disclosure. 
687 consenting HIV-positive individuals (73.2% female; 60.3% ART initiated) were enrolled. 
Reports of any incidence of disclosure to either a family member or sexual partner at enrollment 
and follow-up visits (median 4.4 months post-enrolment) were common (91.0%); however, reports 
of disclosure specifically to sexual partners were relatively rare (34.1%), especially in women 
(29.8%). Participants not engaged in a stable partnerships, not ART-imitated, and/or who had 
disclosed to their family were at risk of non-disclosure to sexual partners. These data highlight 
both an urgent need to empower HIV-positive individuals, and the significant barriers to targeting 
sero-discordant couples for HIV prevention in this setting.
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Introduction
In people living with HIV/AIDS (PLWHA), disclosure of HIV-positive status is positively 
associated with increased access to key support networks, improvements in mental health, 
and earlier initiation and better adherence to anti-retroviral therapy (ART) (1–5). 
Consequently, those PLWHA that disclose their HIV status have been reported to have 
delayed disease progression compared to those who have not disclosed, and may also be less 
likely to transmit HIV to their sexual partner(s) (6).
Beyond early treatment initiation, disclosure of HIV-positive status specifically to a sexual 
partner may have independent HIV prevention benefits, allowing couples to make informed 
decisions concerning their HIV prevention and reproductive health requirements (7). 
Moreover, the adoption and therefore success of many current and anticipated preventive 
measures-including voluntary medical male circumcision (VMMC), pre-exposure 
prophylaxis (PrEP), and treatment-as-prevention (TasP)-may depend largely on couples 
discovering HIV sero-discordancy via mutual disclosure.
Despite the potential importance and benefits of disclosure of HIV-positive status, reported 
incidences and determinants of disclosure have not been extensively reported, especially in 
hyper-endemic settings (8). Previous studies have highlighted the gender, marital and 
employment status of the discloser as important disclosure determinants, whilst fear of 
enacted stigma has frequently been cited as reason for non-disclosure, especially amongst 
women (2, 8–11). However, whilst these studies are informative, a more nuanced and 
context-specific understanding of disclosure is urgently required in HIV prevention priority 
regions in order to inform HIV prevention programs. Indeed, to support disclosure, it is 
important to recognize that determinants of disclosure may vary according to the 
characteristics both of the person disclosing and to the person being disclosed to. For 
example, whether or not a PLWHA has initiated on ART is likely to impact HIV-positive 
status disclosure characteristics, as the need to take pills and visit clinics may increase the 
visibility of their HIV status to those closest to them. It is also important to qualify when 
disclosures occur, such that any potential windows of opportunity for supported disclosure 
are not lost.
In this prospective cohort study, we aimed to provide evidence to contribute to such a 
nuanced understanding of the incidence and determinants of disclosure in a HIV prevention 
priority region in rural KwaZulu-Natal, South Africa.
Methods
Study design and setting
This prospective open-cohort study was conducted between June 2006 and August 2009 at 
the CAPRISA Vulindlela Clinical Research site, approximately 150km west of Durban in 
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KwaZulu-Natal. Vulindlela is a rural community characterized by limited infrastructure, 
poor economic opportunity and high HIV prevalence (12). Free access to ART and pre-ART 
care has been provided since 2004 through the CAPRISA AIDS Treatment (CAT) program, 
funded by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the Centers 
for Disease Control and Prevention. ART eligibility through CAT followed the South 
African Department of Health guidelines in place at the time viz. CD4+ T-cell count ≤200 
cells/µL or clinical stage IV disease.
Study enrollment
Consenting, HIV-positive adults were enrolled from the Vulindlela CAT program. 
Eligibility criteria for participants were: age ≥18 years old; confirmed HIV-positive sero-
status; ability to self-care; residence in the Vulindlela sub-district with no plans to move 
during the study period; non-active treatment for tuberculosis; and willingness to adhere to 
the study follow-up schedule.
In order to understand disclosure characteristics and determinants in participants stratified 
by treatment status, eligible participants were consecutively enrolled into one of two study 
arms, one consisting of participants who had not yet been initiated on ART, and the other 
consisting of participants who had initiated ART; enrolment into these arms was performed 
in a 1:2 ratio, with a target of 700 individuals.
Study Procedures
Written informed consent was obtained from each study participant in the preferred 
language of the interviewee (isiZulu or English) prior to enrollment.
Those participants who had not been initiated on ART were enrolled into the study at their 
first CAT program visit after testing HIV-positive, whilst participants initiated on ART were 
enrolled into the study at their next scheduled clinic appointment.
Socio-demographic characteristics, clinical characteristics, and HIV-positive status 
disclosure histories of participants were recorded through structured questionnaires 
administered by trained study staff at enrollment. HIV-positive status disclosure histories 
were obtained specifically by asking participants if they had told anyone about their HIV 
status, and if so, to whom had they disclosed. At follow-up 3–12 months post-enrollment, 
participants were asked if they had told anyone about their HIV status since their last 
interview, and if so, to whom they had disclosed. Disclosures of HIV-positive status were 
categorized into partner disclosure (disclosure to any marital or sexual partner), family 
disclosure (any disclosure to a sibling, parent, or other relative, including those by marriage) 
or other disclosure. Clinical data on ART initiation date and CD4+ T-cell count were 
collected as part of routine clinical assessment for HIV/AIDS care.
The study protocol was approved by the Biomedical Research Ethics Committee (BREC) of 
the Nelson R. Mandela School of Medicine, Faculty of Health Sciences, University of 
KwaZulu-Natal in Durban, South Africa.
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Descriptive statistics were used to characterize the cohort demographics and clinical 
features, overall and stratified by ART status and gender. Differences in characteristics 
between ART naïve and ART experienced groups, as well as between males and females, 
were tested using either Fisher’s exact test (categorical data) or Wilcoxon Rank Sums test 
(continuous data). An adjusted logistic regression model was used to determine factors 
associated with any partner disclosures reported at enrolment. All statistical analyses were 
performed in SAS (version 9.3; SAS Institute Inc., Cary, NC, USA).
Results
Socio-demographic and clinical characteristics of participants at enrollment
A total of 687 HIV-positive participants aged 28–38 years were enrolled into the cohort, the 
majority of whom were female (73.2%). Overall, female participants were significantly 
younger (median 31 years vs. 34 years; p=0.005) and had significantly higher CD4+ cell 
counts (137 cells/uL versus 206 cells/uL; p<0.001) compared to male participants (Table I). 
Compared to those who had not initiated ART, those participants who had initiated ART 
(60.3%) had expectedly been living with an HIV-positive diagnosis significantly longer 
(median 204 days vs. 56 days; p<0.001), and had significantly lower CD4+ cell counts 
(median 138 cells/µl vs. 346 cells/µl; p<0.001).
Consistent with high levels of unemployment in rural KwaZulu-Natal, 81.5% of participants 
had no formal work and a significant proportion had no secondary education (41.4%). Most 
participants enrolled reported being single or having a casual partner (66.2%), and only a 
minority were married or engaged in a stable relationship (13.7%).
Disclosure of HIV-positive status by participants at enrolment
At enrolment, a median of approximately six months after HIV-positive diagnosis, the vast 
majority of participants (88.9%) had disclosed their HIV-positive status to at least one 
family member or sexual partner (Table II). A lack of disclosure to any family or sexual 
partner was significantly more likely in those participants who had not initiated ART (19.0% 
vs. 5.8%; p<0.001).
Overall, reports of disclosure of HIV-positive status to a member of family were common, 
especially in those participants who had initiated ART (87.7% vs. 67.0%; p<0.001). 
Regardless of ART initiation status, female participants were more likely to have disclosed 
to a family member compared to male participants (82.7% vs. 70.6%; p<0.001).
Despite the majority of participants disclosing their status to one or more family members, 
less than one third (29.4%) of participants reported that they had disclosed their HIV-
positive status to a sexual partner. In both ART naïve and ART experienced participants, 
there was a very notable difference between female and male disclosure to sexual partners, 
with disclosure in female participants being significantly less common than in male 
participants (23.7% vs. 45.1%; p<0.001).
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Incidence of new disclosures between enrollment and follow-up
Follow-up occurred a median of 4.4 months (IQR 3.0–6.4) post-enrollment, with no 
significant differences in follow-up time between ART-experienced and ART-naïve 
participants overall (p=0.779), or sub-stratified by gender (p=0.434 in ART naïve; p=0.321 
in ART experienced). Over follow-up, a total of 218 new disclosures were reported to 
family members, compared to 67 new disclosures reported to partners (Table II).
The incidence of new disclosures to sexual partners was found to be significantly higher in 
male participants initiated on ART compared to female participants initiated on ART (40.6 
disclosures/100 person years [PY] vs. 16.0 disclosures/100 PY; p=0.003). Significant 
differences in the incidence of new disclosures to sexual partners were not observed between 
males and females not initiated on ART (43.5 disclosures/100 PY vs. 30.9 disclosures/100 
PY; p=0.418), nor between participants initiated and not initiated on ART (33.8 
disclosures/100 PY vs. 23.4 disclosures/100 PY; p=0.142).
The incidence of disclosure to family members remained relatively constant across 
participants, with no significant differences observed either between male and female 
participants, or ART initiated and uninitiated participants.
Time to disclosure of HIV-positive status
Figure 1 shows a Kaplan-Meir plot highlighting the time to any incidence of disclosure for 
participants from first HIV positive diagnosis. Overall, the majority (67.3%) of disclosures 
described by participants either at enrolment or follow-up were reported to have occurred on 
the day of HIV diagnosis. A further 18.4% of disclosures were reported to have occurred 
within a month of HIV-positive diagnosis, and 14.3% were reported to have occurred more 
than a month following HIV-positive diagnosis.
The proportion of disclosures occurring more than a month post-HIV-positive diagnosis 
were significantly higher for those participants initiated on ART compared to those who had 
not been initiated (19.8% vs. 5.0%; p<0.001), suggesting that despite a large proportion of 
disclosures occurring very close to HIV-positive diagnosis, disclosures do continue to occur 
over time, and may be catalyzed by ART initiation. Amongst those participants initiated on 
ART, females were more likely to disclose later (more than a month post-HIV-positive 
diagnosis) compared to males (21.4% vs. 16.4%; p=0.079).
Predictors of disclosure of HIV-positive status to sexual partner
Given the importance of HIV-positive status disclosure to sexual partners for HIV 
prevention interventions, we used an adjusted logistic regression model to determine factors 
associated with any partner disclosures reported at enrolment, in an attempt to better 
characterize those participants most and least likely to disclose to their sexual partners.
In an initial model (data not shown), we found female participants to be 64% less likely than 
male participants to disclose to their partners (adjusted odds ratio [aOR]=0.36; confidence 
interval [CI] 0.22–0.61; p<0.001). As such, we performed all subsequent analyses stratified 
by gender (Table III).
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For male participants, having a stable partner was significantly associated with an 
approximately 6-fold increased likelihood of partner disclosure (aOR=6.42; CI 1.22–33.94; 
p=0.029). Partner disclosure was also more likely if males were employed (aOR=2.47; CI 
0.88–7.00; p=0.088), and less likely if males had disclosed to their family (aOR=0.33; CI 
0.10=1.08; p=0.067); however, these associations were not statistically significant.
In female participants, initiation of ART (aOR=2.44; CI=1.32–4.52; p=0.004) and having a 
stable partner (aOR=2.41; CI=1.21–4.80; p=0.004) were both significantly positively 
associated with partner disclosure. In contrast, older female participants (aOR per year 
increase=0.93; CI=0.93–0.99; p=0.033) and female participants that had disclosed to their 
families (aOR=0.39; CI=0.19–0.79; p=0.009) were less significantly less likely to have 
disclosed to their partners.
Discussion
Despite significant overall levels of disclosure of HIV-positive status, disclosure of status 
specifically to sexual partners in this setting is very low, particularly in females. Indeed, 
only approximately one third of participants reported to have disclosed their HIV status to a 
partner between HIV-positive diagnosis and the end of the study (a period of approximately 
10 months).
The high overall levels of disclosure are reassuring, and suggest that the majority of 
PLWHA in this setting have access to at least some support networks (2). However, low 
rates of disclosure to sexual partners are concerning, and may impact on the demand and 
thus the uptake of a number of HIV prevention modalities (including condom use, TasP, 
PrEP, and VMMC) as many couples may not have an accurate perception of their HIV 
acquisition risk.
Although participants were not asked specifically about why they choose not to disclose to 
their sexual partners, those participants who were female, not engaged in a stable 
partnerships, not initiated on ART, and who had disclosed to their family were all at risk of 
non-disclosure to their sexual partners.
The low rates of sexual partner disclosure among female participants compared to male 
participants are suggestive of significant gender-power imbalance within couples in this 
community, and are consistent with previous qualitative studies that have highlighted fear of 
enacted stigma and gender-based violence as significant barriers to disclosure (11). 
Importantly, this gender-disparity in disclosure may augment the effects of non-disclosure in 
this and similar settings, where women carry a disproportionate burden of HIV infection 
(13).
Furthermore, although disclosure of HIV-positive status to sexual partners was more 
common in stable relationships than in casual relationships, reports of such relationships 
were rare, and even in these relationships only approximately 50% of participants reported 
disclosing. These data have important implications for the programmatic scale-up of new 
prevention technologies. Indeed, if PrEP and TasP are to be targeted only at stable sero-
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discordant couples in an attempt to maximize resource-efficiency (14), the lack of stable 
couples and non-disclosure of HIV status reported here may represent significant barriers.
Interestingly, those participants who were initiated on ART were more likely to have 
disclosed to their sexual partners compared to those who had not started treatment. This 
effect was found to be independent from the length of time participants had been living with 
an HIV-positive diagnosis, suggesting that it cannot be explained fully by a greater 
acceptance of their HIV-positive status with time. Indeed, together with our data on time-to-
disclosure, these data highlight that ART initiation may act as a catalyst for new disclosures, 
and that following a ‘first window’ on the day of HIV-positive diagnosis, ART initiation 
represents a ‘second window’ of opportunity for disclosure. Moreover, support for 
disclosures during this time-particularly to women-may be an efficient strategy for 
initiatives aiming to increase overall disclosure levels. Further analysis of the data obtained 
from this and other studies is needed to confirm this hypothesis (for example, a priority is to 
explore those participants who initiated ART during the follow-up period, or who recently 
initiated ART at enrollment), and to understand how it is mediated, although we propose 
that is may result from a greater need to disclose with the greater visibility imposed by 
treatment regimens and clinic visits.
A second novel result from our study was the observation of a degree of mutual exclusivity 
between disclosures to sexual partners and disclosures to family. Indeed, disclosure to 
sexual partners was overall approximately 65% less likely if participants had disclosed to 
their family. This pattern could be explained if we consider that participants are largely only 
disclosing to those from whom they cannot hide their HIV status, for example, those who 
they live with. Alternatively, enacted stigma on an initial disclosure could deter further 
disclosures. Future studies should aim to investigate these and other potential hypotheses, as 
both present significant challenges to supporting disclosures.
The data presented should be interpreted in light of the methodological limitations of the 
study. Indeed, the time to follow-up was quite variable in an attempt to minimize burden of 
study participant beyond normal CAT visits for participants. As an adjustment, ‘disclosure 
incidence’ was calculated, but comparisons of this measure with traditional incidence 
measures should be cautioned as the nature of disclosure is different to, for example, HIV 
incidence (disclosure can occur multiple times, but may become less frequent over time as 
people to disclosure to become limiting). Further, participants were not asked about their 
number and frequency of current sexual partnerships, thus it is difficult to determine if low 
reported partner disclosure are simply the result of participants having limited contact with 
partners. Despite such limitations, the study highlights an urgent need to better understand 
characteristics and trends in HIV-positive status disclose in order to inform the design both 
of interventions to support disclosure, and also more broadly of HIV prevention 
interventions.
Strategic interventions to empower PLWHA –particularly women-to disclose their HIV 
status to their sexual partners are clearly important both to create demand in couples for HIV 
prevention technologies, and for their own clinical benefit. Services providing couples’ 
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counseling, testing, and/or treatment initiation may allow for controlled disclosure between 
sexual partners, minimizing the risks of enacted stigma or gender-based violence (15).
However, whilst important, these interventions may take significant time to implement, and 
in this setting may be limited by the low rates of stable partnerships. Furthermore, in this 
and similar high-burden communities, it may be more efficacious as a first step to target 
prevention interventions such as TasP and PrEP to specific geographies and key high 
incidence populations such as adolescent girls and young women(16), as opposed to 
depending on identification of sero-discordant couples via sexual partner disclosure.
Considering the cultural and behavioral context in addition to understanding the local 
epidemiology will be critical both in ensuring the success of programmatic scale-up of 
combination HIV prevention, and ultimately in reaching our goals of epidemic control.
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Kaplan-Meier curve showing time to any reported incidence of disclosure from HIV 
diagnosis
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